First-in-Class Insulin Sensitizers
DeveloGen's insulin sensitizers are first-in-class oral anti-diabetic drugs. They address insulin resistance directly and thus the primary cause of type 2 diabetes and other insulin resistance related disorders.

Type 2 Diabetes
The development of type 2 diabetes mellitus is mainly driven by insulin resistance and beta cell failure. Insulin resistance, the body's inability to properly respond to an insulin signal, pushes pancreatic beta cells to produce and release more insulin into the blood stream in order to ensure that blood sugar levels are kept at appropriate levels. Patients with insulin resistance develop overt diabetes once the beta-cells start to degenerate and fail to provide adequate plasma insulin levels. Inadequate supply of insulin leads to increased blood sugar levels which are associated with the development of long-term complications. Currently available treatments largely address symptoms but are unable to stop or even reverse the progression of type 2 diabetes

DeveloGen's approach is to target insulin resistance and beta cell failure, the two underlying causes of type 2 diabetes, directly. Our first-in-class insulin sensitizers block signals that negatively interfere with the transduction of the insulin signal and thereby increase the capacity the body's cell to respond to insulin. DeveloGen's first in class beta cell regeneration factor is a secreted molecule that stimulates beta cell proliferation and neogenesis and thereby promotes the regeneration of the beta cell mass and ensures that the body is able to provide sufficient endogenous insulin to maintain proper glycemic control.

Targeting Insulin Resistance
DeveloGen's insulin sensitzers act on a novel and proprietary target identified and validated by DeveloGen. Whereas elevated target activity leads to insulin resistance, decreased target activity leads to increased insulin sensitivity and thus improved glycemic control, normalized lipid profiles, the preservation of beta cell mass and overall a decrease in body weight. DeveloGens insulin sensitzers are currently in advanced lead optimization stages and have demonstrated to be superior in efficacy compared to existing therapies in preclinical models. They are able to increase insulin sensitivity, normalize blood glucose and lipid levels, and preserve the beta cell mass without causing weight gain.